Objective. The aim of the present study was to explore the long-term outcome and clinical characteristics of adult patients with juvenile onset in the EULAR Scleroderma Trials and Research (EUSTAR) cohort and compare them with adult patients with onset between 20 and 40 years of age.
Introduction
Juvenile SSc (jSSc) is a rare disease in childhood, with an estimated incidence of 0.05 per 100 000 [1] and a prevalence of 1 in 1 000 000. It has been hypothesized that 10% of all SSc patients develop the disease before the age of 16 years but nothing is known about whether puberty has any influence on the incidence. One of the major problems that has to be discussed frequently with a jSSc patient and his/her family is the long-term outcome of the disease. Obviously survival of the affected patient is a pivotal problem, and it is known that the 5-year survival of jSSc patients ranges between 95% [2] and 93% [3] according to the two existing multinational retrospective paediatric surveys. Approximately 90% of the patients in these paediatric cohorts are affected by the diffuse form of SSc; this appears to be a different disease pattern compared with the adult cohorts. However, at present, only few data are available addressing the long-term outcome of these patients from youth to adulthood. Therefore the purpose of our study was to explore the long-term outcome and clinical characteristics of adult patients with juvenile onset SSc (jSSc) and compare them with young adult-onset SSc (aSSc) patients from the European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) [4] .
Methods
Up to April 2006, 5000 patients were registered in the EUSTAR database [4] . Patients were classified according to the ACR preliminary classification criteria [5] , and the subset was defined according to the LeRoy criteria [6] . In this database, data of the patients were collected in the Minimal Essential Data Set (MEDS) [MEDS parameters and video coaching material are also available at the EUSTAR website (http://www.eustar.org)] [4] , which has been established by a consensus process of the EUSTAR members. It covers demographic aspects, disease duration, organ involvement and laboratory data. Patient data were extracted from this database, selecting subjects with the first non-Raynaud presentation before the age of 16 years. This group was split into earlyonset jSSc, onset of first non-Raynaud symptoms before the age of 10 years (prepubertal) and late-onset (pubertal) jSSc with age of onset after the age of 10 years. (The mean age of girls starting puberty reaching Tanner stage 2 is between 9.5 and 9.7 years [7] , and for boys with systemic JRA it is 10.8 years [8] . This explains the cut-off at the age of 10 years.) We chose as comparison patients who had the first non-Raynaud presentation between 20 and 40 years of age. Demographic data, organ involvement, laboratory data and outcome of these patients were evaluated according to the guidelines of the MEDS database [4] . A comparison with previous published series was performed using the Student's t-test for statistical analysis with the significance set at P < 0.05.
Results
Sixty patients (1.2% of the whole EUSTAR cohort) with jSSc (juvenile onset, age of onset before the age of 16 years) were identified, 55 females and 5 males (female : male = 11 : 1). Interestingly, when we divided patients by age of onset before or after the age of 10 years, the male/female ratio was significantly different between the two groups (P = 0.012). It was 1 : 2.75 before 10 years of age compared with 1 : 21.5 between 10 and 16 years of age ( Table 1 ). The disease subset distribution also differed: patients with prepubertal onset had an increased proportion of diffuse subset patients: 60% compared with 35% (P = 0.192). None of the prepubertal patients had ACAs (P = 0.673). The modified Rodnan skin score was significantly higher in patients with prepubertal onset: 17.5 compared with 10.7 in those with onset after the age of 10 but < 16 years (P = 0.027). Interestingly, patients with prepubertal onset had less gastrointestinal involvement (P > 0.05). The proportions of patients with pulmonary fibrosis were similar. The mean age at disease onset in the whole jSSc group was 12.4 years (range 215.9) with a mean disease duration of 17.6 years (1.854.8).
The aSSc (adult-onset) group, age of onset between 20 and 40 years, consisted of 910 patients (representing 18% of the EUSTAR cohort). In all, 810 of the patients were females and 100 were males (male : female = 1 : 8.1). Mean age at disease onset was 32 years (range 2040). The mean disease duration was 12.5 years (247.5). The disease was active according to EUSTAR activity score [4] at the time of last follow-up in 26.6% of jSSc patients and 24.8% of aSSc patients. In jSSc, 59 (98%) of the 60 patients were alive at the last follow-up and 1 was lost to follow-up. In aSSc, 898 (99%) patients were alive at the last follow-up, 7 died and 5 were lost to follow-up ( Table 2 ). The distribution of the disease subsets was statistically not different. In the whole jSSc group, 42% of patients had a diffuse subset, 49% had a limited subset and 9% had an overlap syndrome. In aSSc, 38.2% of patients had a diffuse subset, 53.1% had a limited subset and 8.7% had an overlap syndrome ( Table 2 ).
The antibody profile was also comparable with regard to the presence of ANA: 90% in the jSSc group and 92.8% in the aSSc group. Anti-Scl-70 was positive in 40% of the jSSc and 40.7% of aSSc patients. There was a significant difference in the frequency of ACAs, 5% in the jSSc group and 27.8% in the aSSc group (P < 0.005) ( Table 2) . Organ involvement showed a similar pattern in the two groups of patients at the time of the last follow-up (Table 3) , with no significant difference in any of the evaluated and affected organs.
Discussion
Our study shows interesting differences in prepubertaland pubertal-onset patients with adult jSSc. Prepubertal children have a significantly increased proportion of male patients and significantly higher mean modified Rodnan skin score (Table 1 ). The main difference between jSSc and aSSc patients is the significantly decreased frequency of ACAs in the jSSc patients. Scalapino et al. [9] and Foeldvari et al. [13] found a similar decreased frequency of ACAs in a similar study looking at paediatriconset patients in adulthood (Table 4 ). It could be hypothesized that this reflects the predominance of the diffuse subset in childhood, persisting only in the antibody profile but not in the amount of skin involvement. As adult patients were characterized by the physician currently treating them, they could have had diffuse-onset disease in childhood. In our jSSc cohort, the number of patients with anti-Scl 70 was 40% compared with 33% in the Royal Free cohort [12] and 23% in the Pittsburgh cohort [9] . Despite the difference in antibody expression, we could not demonstrate significant differences regarding organ involvement between the groups in the EUSTAR cohort. These results are in contrast to the data from Scalapino et al. [9] , in which the study groups were www.rheumatology.oxfordjournals.org defined as onset of disease before the age of 16 years and young adults with onset of disease between 16 and 40 years of age. They found significant differences in organ involvement: the mean modified skin score at presentation and the frequency of renal crisis were lower in the juvenile-onset group, whereas skeletal muscle involvement was twice as frequent in the juvenile-onset group [9] . Unlike our study, the Pittsburgh survey also found a significantly higher proportion of jSSc patients with overlap syndrome and this observation was confirmed in the population of the Royal Free cohort [13] .
Although disease duration at last follow-up was similar in the Pittsburgh survey and our cohort, the survival of our paediatric patients was not different from the adultonset patients; survival was worse in the paediatric group in the Pittsburgh cohort [9] . The survival rate in the Royal Free cohort at 5, 10, 15 and 20 years was 100, 98, 95 and 82%, respectively, comparable to that of the EUSTAR cohort. One of the explanations for these differences could be that the recruitment of patients in the Pittsburgh cohort started in 1960, whereas in the EUSTAR cohort and Royal Free cohort the patients were followed and treated more recently. During this time period the mortality of SSc changed significantly [10] , with a better outcome in the current era. Another explanation is the difference in ethnic background of the study populations. This is pointed out in a publication from the Pittsburgh group when comparing the Pittsburgh cohort with a French cohort, where the patients are predominantly Caucasian, with a less severe disease course in the latter [11] . The Caucasian ethnic pattern is also prevalent in the EUSTAR cohort.
The subset distribution in favour of dSSc is unique to this juvenile SSc cohort [3] , whereas the adult juvenileonset patients in all three cohorts have a subset distribution similar to that of adult-onset SSc patients, but the Royal Free cohort and the Pittsburgh cohort consist of a significant proportion of patients (37%) with overlap features [13] . The adult prepubertal-onset patients show a similar increased diffuse subset dominance. This change in the subset distribution over time from paediatric to adult jSSc patients is presumably the result of a survival bias of the limited subset or of decreased skin involvement of diffuse patients over time.
It is noteworthy that the antibody profile is similar in the juvenile-onset cohorts in adulthood (Table 4) , with a low number of patients with ACAs, a feature that appears to be predominant in jSSc patients. In the publication from Data are represented as n (%)/total n, unless otherwise mentioned.
a Some data missing, therefore not 100%.
the Pittsburgh cohort, the assessment and comparison with the EUSTAR cohort for each organ system is difficult due to lack of recorded data. However, hypertension appears to occur more often in the adult juvenile cohort and synovitis occurs more often in the paediatric-age juvenile cohort. The strengths of our data consist in the large number of cases collected and examined by experts in the field using a pre-designed survey tool. A weakness is that it is a cross-sectional survey at many centres without standardized assessment of organ involvement and serology.
Our study presents one of the largest adult jSSc patient cohorts compared with an adult cohort of aSSc patients. Interestingly, the antibody profile with the low frequency of ACAs persists into adulthood. The subset pattern of the jSSc cohort in adulthood resembles that of adult-onset patients in all other ways. Interestingly, we could even show some differences in patients with disease onset before and after 10 years of age; especially interesting is the higher rate of males aged <10 years. The survival bias is presumably related to the higher rate of death in the juvenile-onset diffuse SSc patients between the paediatric age and the time of observation in the EUSTAR cohort or to the decreasing skin involvement over time. To gain knowledge regarding the disease between the paediatric and adult cohorts, the prospective Juvenile Systemic Scleroderma Inception Cohort Project (ww.juvenilescleroderma.com) could help, where new-onset jSSc Data are represented as n (%)/total n, unless otherwise mentioned. patients with a disease course of <18 months are followed prospectively.
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. The subset distribution of jSSc patients in adulthood and the aSSc cohort was similar. . Only the frequency of ACAs was significantly lower in jSSc patients than in adult-onset SSc patients. 
